Leptin and adiponectin concentrations in infants with low birth weight: relationship with maternal health and

Juliana Fernandez Santana-Meneses1, Fabíola I Suano-Souza1,2, Maria do Carmo Franco1

  • 1Universidade Federal de São Paulo, Escola Paulista de Medicina, Pediatrics Department, São Paulo, São Paulo, Brazil.

Insights

Low birth weight (LBW) infants show early changes in leptin and adiponectin, influenced by maternal nutrition and infant growth. These hormonal shifts may increase their risk of developing chronic non-communicable diseases later in life.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Public Health

Background:

  • Infant health significantly impacts long-term risk for chronic non-communicable diseases (NCDs).
  • Leptin and adiponectin play crucial roles in metabolic regulation.
  • Understanding hormonal profiles in low birth weight (LBW) infants is vital for early intervention.

Purpose of the Study:

  • To determine leptin and adiponectin concentrations in LBW infants.
  • To explore associations between these hormones and maternal nutritional status, gestational age adequacy, postnatal weight gain, and current diet.
  • To identify early risk factors for NCDs in LBW infants.

Main Methods:

  • Cross-sectional study of 54 LBW infants aged 9-12 months.
  • Collected data on maternal background, pre-pregnancy nutrition, infant anthropometry (birth and current), nutritional recovery, dietary intake, and blood leptin/adiponectin levels.
  • Analyzed associations using statistical methods, considering factors like small for gestational age (SGA) status and pre-gestational BMI.

Main Results:

  • LBW infants exhibited altered leptin and adiponectin concentrations.
  • Small for gestational age (SGA) infants showed faster weight recovery, higher leptin levels, and increased leptin/adiponectin ratios.
  • Higher maternal pre-gestational BMI modified the relationship between weight-for-age z-score (WAZ) and leptin levels in LBW infants.

Conclusions:

  • LBW infants experience early hormonal changes (leptin, adiponectin) influenced by maternal, intrauterine, and postnatal factors.
  • These early metabolic alterations may predispose LBW infants to an increased risk of NCDs.
  • Maternal pre-gestational BMI is a significant factor in modulating hormonal profiles in LBW infants.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
68
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.2K
Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
1.2K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
58
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
164